Syneos Health Inc News - SYNH

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy...

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in...

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations...

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Data showed ELI-002 administered as a monotherapy induced robust, polyfunctional and durable KRAS specific CD4...

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

BOSTON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

ELI-002 2P promising median relapse-free survival of 16.3 months in AMPLIFY-201 Phase 1a study presented at...

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an...

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting

BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R...

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot...

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Syneos Health Inc (SYNH)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SYNH News

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

SYNH Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Syneos Health Inc (SYNH) News

Syneos Health Inc (SYNH)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SYNH News

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

SYNH Discussion

Your Recent History